Lucid Diagnostics Secures VA Contract for EsoGuard Test, Expanding Esophageal Precancer Testing Across Veterans Affairs Healthcare Facilities.
ByAinvest
Thursday, Jan 22, 2026 1:43 am ET1min read
LUCD--
Lucid Diagnostics (LUCD) has secured a contract with the US Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding availability across the VA healthcare system. The contract aligns with Medicare reimbursement rates and facilitates streamlined procurement. LUCD operates in the healthcare sector, focusing on medical diagnostics technology for esophageal precancer detection. The company has demonstrated revenue growth but faces significant negative margins and financial distress.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet